Bromocriptine-13C-d3 is intended for use as an internal standard for the quantification of bromocriptine (Item No. 14598) by GC- or LC-MS. Bromocriptine is a dopamine receptor agonist (Kis = 1,659, 12.2, 12.2, 59.7, and 1,691 nM for dopamine D1, D2, D3, D4, and D5 receptors, respectively).1 It also binds to the serotonin (5-HT) receptor subtypes 5-HT1A and 5-HT1D (Kis = 12.9 and 10.7 nM, respectively), as well as α1-adrenergic receptors (Kis = 1.12-4.17 nM).1,2 Bromocriptine (5 mg/kg) restores locomotor activity, without inducing dyskinesia, in a macaque model of Parkinson’s disease induced by MPTP.3 Formulations containing bromocriptine have been used in the treatment of Parkinson's disease, hyperprolactinemia-associated dysfunctions, and acromegaly.WARNING This product is not for human or veterinary use.
[1] MSC TROND KVERNMO PhD E B PhD Sebastian Härtter. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists[J]. Clinical therapeutics, 2006, 28 8: Pages 1065-1078. DOI:
10.1016/j.clinthera.2006.08.004[2] MARK J MILLAN. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.[J]. Journal of Pharmacology and Experimental Therapeutics, 2002, 303 2: 791-804. DOI:
10.1124/jpet.102.039867[3] C. ROUILLARD T. D P P J Bédard. Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393[J]. European journal of pharmacology, 1990, 185 2: Pages 209-215. DOI:
10.1016/0014-2999(90)90642-j
